Document is current
Any future updates will be listed below
-
Authors
Yarmarkovich, Mark
Marshall, Quinlen F. https://orcid.org/0000-0002-4736-9716
Warrington, John M. https://orcid.org/0000-0001-6066-5491
Premaratne, Rasika
Farrel, Alvin https://orcid.org/0000-0003-1087-9840
Groff, David https://orcid.org/0000-0001-6897-2656
Li, Wei
di Marco, Moreno
Runbeck, Erin
Truong, Hau
Toor, Jugmohit S.
Tripathi, Sarvind https://orcid.org/0000-0002-6959-0577
Nguyen, Son https://orcid.org/0000-0002-0475-5158
Shen, Helena https://orcid.org/0000-0002-0500-441X
Noel, Tiffany
Church, Nicole L.
Weiner, Amber
Kendsersky, Nathan https://orcid.org/0000-0003-0132-8748
Martinez, Dan
Weisberg, Rebecca
Christie, Molly
Eisenlohr, Laurence
Bosse, Kristopher R.
Dimitrov, Dimiter S. https://orcid.org/0000-0002-2258-1024
Stevanovic, Stefan
Sgourakis, Nikolaos G.
Kiefel, Ben R.
Maris, John M. https://orcid.org/0000-0002-8088-7929
- License Information
-
More Information
Article History
Received: 23 March 2023
Accepted: 3 October 2023
First Online: 8 November 2023
Competing interests
: J.M.M. and M.Y. have equity stake in Tantigen Bio and HuLA Therapeutics. Both companies have interest in commercializing technologies described herein. B.R.K. is an employee of and has equity interests in Myrio Therapeutics. R.P. and N.L.C. are employees of Myrio Therapeutics. J.M.M., M.Y., N.G.S. and B.R.K. are co-inventors on a patent filed regarding the PHOX2B PC-CAR.
